Lower threshold for admission in frail or cognitively impaired patients
Limited home support for IV antibiotic completion
Swallow dysfunction prevalence increases falls and aspiration risk
Functional status reassessment critical for discharge planning
Pediatrics
Epidemiology in children
Legionnaires disease less common in immunocompetent children
Nosocomial cases in neonatal and pediatric ICU settings
Immunocompromised children (transplant, oncology) at highest risk
Antibiotic selection in children
Azithromycin — first-line for children
10 mg/kg once daily (maximum 500 mg) PO or IV
Duration: 5-7 days immunocompetent; up to 10 days immunocompromised
Levofloxacin — acceptable when azithromycin not suitable
8-10 mg/kg IV or PO twice daily for children < 5 years (maximum 250 mg per dose)
10 mg/kg once daily for children >= 5 years (maximum 500 mg)
Use restricted to severe or fluoroquinolone-indicated cases
Doxycycline — avoid in children < 8 years (dental staining)
May be used in children >= 8 years: 2.2 mg/kg per dose twice daily (maximum 100 mg per dose)
Clinical features in children
Similar to adults but GI symptoms and neurological involvement may predominate
Diarrhea and confusion in school-age children and adolescents
Rhabdomyolysis less frequent than in adults
Respiratory failure management
Age-appropriate oxygen thresholds and tidal volume targets
Feeding intolerance as severity marker in infants
Background
Epidemiology
Incidence and burden
Legionella accounts for approximately 5% of all-cause community-acquired pneumonia
One of three most common causes of CAP requiring ICU admission
Notifiable disease in most jurisdictions worldwide
Mortality range 4-40% depending on host factors and treatment timing
Higher mortality in immunocompromised and ICU patients
Early appropriate antibiotic therapy significantly reduces mortality
Approximately one-third of cases require ICU-level care
Demographics
Age > 50 years and male sex predominate
Rare in immunocompetent children
Seasonal peak: June-October (Northern Hemisphere)
Relates to cooling tower use and warm-water system proliferation
Sporadic and outbreak forms
Sporadic cases: individual exposures to contaminated water
Outbreak cases: shared water source (hotel, hospital, cooling tower)
Causative organisms
Legionella pneumophila serogroup 1: 80-90% of community-acquired cases
Other serogroups and non-pneumophila species account for remaining cases
Non-serogroup 1 strains missed by urinary antigen test
Over 60 Legionella species identified; approximately 20 associated with human disease
Pathophysiology
Mechanism of infection
Inhalation of aerosolized water droplets containing Legionella
Person-to-person transmission does not occur
Water system contamination is required source
Obligate intracellular pathogen
Survives and replicates within alveolar macrophages
Evades phagolysosomal killing — explains why beta-lactams are ineffective
Intracellular location requires agents with intracellular penetration (macrolides, fluoroquinolones)
Multiorgan involvement
Pulmonary: alveolar macrophage invasion leading to pneumonia and ARDS
Renal: direct invasion and rhabdomyolysis-related acute tubular necrosis
Neurological: mechanisms include direct CNS invasion, hyponatremia, and inflammatory cytokines
Cardiac: myocarditis and pericarditis via direct tissue invasion and systemic inflammatory response
Hepatic: transaminase elevation from direct invasion and systemic inflammation
Immune response
Cell-mediated immunity is primary host defense
T-cell activation required for macrophage bactericidal function
Explains severity in T-cell-deficient states (transplant, hematologic malignancy, HIV)
Humoral immunity less protective
Antibody production delayed and incomplete
Therapeutic Considerations
Antibiotic mechanism of action
Fluoroquinolones: inhibit DNA gyrase and topoisomerase IV with excellent intracellular penetration
Achieve high intracellular concentrations in alveolar macrophages
Superior time to clinical stability in meta-analysis (Jasper 2021)
Macrolides: inhibit bacterial protein synthesis; concentrate in macrophages and lung tissue
Immunomodulatory effects may provide additional benefit
Doxycycline: tetracycline class with intracellular activity
Acceptable alternative when fluoroquinolone and macrolide not suitable
Beta-lactams and aminoglycosides are ineffective
Cannot penetrate intracellular compartment where Legionella resides
Radiographic progression paradox
>50% of patients show imaging progression in first week despite appropriate antibiotics
Expected phenomenon — do not change or add antibiotics based on imaging alone
Clinical improvement (fever, respiratory status) is the primary treatment response measure
Radiographic clearance lags behind clinical improvement by weeks
Combination therapy evidence
No evidence supports combination macrolide plus fluoroquinolone over monotherapy
Even in severe disease — Cunha et al. 2016
ACEP Level B recommendation for monotherapy with appropriate intracellular agent
Prevention
Water system maintenance and decontamination is primary prevention
Superheating (>60 degrees C) and chlorination of building water systems
Cooling tower maintenance with biocides
No vaccine available for Legionella
Patient Discharge Instructions
copy discharge instructions
Legionnaires disease home care instructions
Take antibiotics exactly as prescribed until the full course is completed
Do not stop antibiotics early even if feeling better
Complete the full prescribed duration
Rest and stay well hydrated
Drink at least 8 glasses of water or clear fluids daily
Avoid alcohol during antibiotic course
Manage fever
Acetaminophen or ibuprofen as directed for fever and muscle aches
Fever may persist for several days after starting antibiotics
Warning signs — return to emergency department immediately
Worsening shortness of breath at rest
New oxygen requirement or home oxygen saturation below 92%
Chest pain
Blue or grey lips or fingernails
Confusion, difficulty thinking clearly, or loss of consciousness
Recurrent high fever after initial improvement
Dark or bloody urine or significantly decreased urine output
Persistent vomiting or inability to keep down oral medications or fluids
Expected recovery course
Clinical improvement typically within 3-5 days of appropriate antibiotics
Fatigue, weakness, and cognitive symptoms may persist for weeks to months after recovery
Radiographic resolution on chest X-ray may lag behind clinical recovery by weeks
No transmission to household contacts
Legionella is not spread person-to-person
Household contacts do not require antibiotics or testing
Follow-up plan
Primary care or specialist follow-up within 1-2 weeks of discharge
Repeat chest X-ray at 6-8 weeks to confirm resolution
Especially important for smokers and patients over 50 years to exclude underlying lung disease or malignancy
Public health follow-up may contact you regarding environmental investigation
References
Guidelines and key sources
Primary clinical guidelines
IDSA and ATS: Diagnosis and Treatment of Adults With Community-Acquired Pneumonia — Metlay JP et al., American Journal of Respiratory and Critical Care Medicine, 2019
IDSA and ASM: Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases, 2024 Update — Miller JM et al., Clinical Infectious Diseases, 2024
File TM, Ramirez JA: Community-Acquired Pneumonia — New England Journal of Medicine, 2023
Key Legionella references
Rello J, Allam C, Ruiz-Spinelli A, Jarraud S: Severe Legionnaires Disease — Annals of Intensive Care, 2024
Cunha BA, Burillo A, Bouza E: Legionnaires Disease — Lancet, 2016
Phin N, Parry-Ford F, Harrison T et al: Epidemiology and Clinical Management of Legionnaires Disease — Lancet Infectious Diseases, 2014
Diagnostic and treatment evidence
Jasper AS, Musuuza JS, Tischendorf JS et al: Fluoroquinolones versus macrolides for Legionella pneumonia — Clinical Infectious Diseases, 2021
Avni T, Bieber A, Green H et al: Diagnostic Accuracy of PCR versus urinary antigen for Legionella — Journal of Clinical Microbiology, 2016
Sopena N, Sabria-Leal M, Pedro-Botet ML et al: Comparative Clinical Presentation of Legionella versus other CAP — Chest, 1998
Imaging and outcomes
Kim KW, Goo JM, Lee HJ et al: CT findings and clinical features of Legionella pneumonia — Journal of Computer Assisted Tomography, 2007
Shroff GS, Marom EM, Wu CC et al: Pulmonary Legionellosis in oncologic patients on CT — Journal of Computer Assisted Tomography, 2016
Allgaier J, Lagu T, Haessler S et al: Risk factors, management and outcomes of Legionella pneumonia — Chest, 2021
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.